Buckhead Capital Management LLC Buys 762 Shares of GSK plc (NYSE:GSK)

Buckhead Capital Management LLC lifted its stake in shares of GSK plc (NYSE:GSK) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 107,053 shares of the pharmaceutical company’s stock after purchasing an additional 762 shares during the period. GSK accounts for 1.5% of Buckhead Capital Management LLC’s holdings, making the stock its 28th biggest position. Buckhead Capital Management LLC’s holdings in GSK were worth $3,967,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in GSK. Provident Trust Co. boosted its stake in shares of GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after acquiring an additional 1,297,385 shares during the period. FMR LLC boosted its stake in shares of GSK by 7.7% during the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after acquiring an additional 1,291,161 shares during the period. Kahn Brothers Group Inc. bought a new position in shares of GSK during the 3rd quarter worth approximately $46,483,000. Adage Capital Partners GP L.L.C. bought a new position in shares of GSK during the 3rd quarter worth approximately $45,114,000. Finally, Morningstar Investment Services LLC boosted its stake in shares of GSK by 1,684.1% during the 3rd quarter. Morningstar Investment Services LLC now owns 1,136,495 shares of the pharmaceutical company’s stock worth $41,300,000 after acquiring an additional 1,072,792 shares during the period. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent research reports. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Morgan Stanley began coverage on GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy”.

GSK Stock Up 2.7 %

Shares of NYSE GSK traded up $1.13 during midday trading on Wednesday, hitting $42.57. 4,256,293 shares of the stock traded hands, compared to its average volume of 3,463,409. The company has a market cap of $88.22 billion, a PE ratio of 13.76, a P/E/G ratio of 1.46 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. GSK plc has a one year low of $33.33 and a one year high of $43.84. The business has a 50 day moving average price of $41.81 and a two-hundred day moving average price of $39.04.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The business had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. On average, equities analysts predict that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were paid a $0.3564 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.35%. GSK’s payout ratio is presently 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.